Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma
In brief
Adding personalized therapy lifts 2-year melanoma recurrence-free survival from 70% to 82%
In a phase 3 trial of resected high-risk melanoma, adding intismeran to pembrolizumab raised 2-year recurrence-free survival to 82.2%, versus 70.0% with pembrolizumab alone; distant-metastasis-free survival also improved. Severe adverse events were somewhat more common with the combination, and the benefit emerged after six months. Longer follow-up will show whether these gains persist.
- Journal
- The New England journal of medicine (Q1)
- Published
- 11 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Georgina V Long, Muhammad A Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo S Carlino, et al.
- PMID
- 43013837
- DOI
- 10.1056/NEJMoa2609762
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (top studies of the week, 15 November 2026): Phase III randomized trial of adjuvant neoantigen therapy
- Picked for Dermatology (top studies of the week, 15 November 2026): Phase III randomized trial of adjuvant therapy for resected melanoma
Abstract
BACKGROUND: Intismeran autogene (intismeran) is an individualized neoantigen therapy that is designed to induce new T-cell responses and expand preexisting T-cell responses against patient-specific tumor neoantigens, which may potentially improve the efficacy of adjuvant therapy in patients with melanoma. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with completely resected stage IIB to IV cutaneous melanoma in a 2:1 ratio to receive intramuscular intismeran (at a dose of 1 mg) or placebo every 3 weeks for nine doses; all the patients received intravenous pembrolizumab (at a dose of 400 mg) every 6 weeks for nine cycles. The primary end point was investigator-determined recurrence-free survival, assessed in a time-to-event analysis. Key secondary end points included investigator-determined distant-metastasis-free survival (assessed in a time-to-event analysis) and safety. RESULTS: A total of 1137 patients underwent randomization: 757 to the intismeran-pembrolizumab group and 380 to the placebo-pembrolizumab group. The median follow-up was 24.6 months. Recurrence-free survival at 24 months was 82.2% in the intismeran-pembrolizumab group and 70.0% in the placebo-pembrolizumab group (two-sided P<0.001); the piecewise hazard ratio was 0.99 (95% confidence interval [CI], 0.66 to 1.49) before 6 months and 0.42 (95% CI, 0.30 to 0.58) after 6 months. Distant-metastasis-free survival at 24 months was 88.5% with intismeran-pembrolizumab and 80.2% with placebo-pembrolizumab (two-sided P = 0.002); the piecewise hazard ratio was 1.01 (95% CI, 0.58 to 1.79) before 6 months and 0.50 (95% CI, 0.34 to 0.73) after 6 months. Adverse events of grade 3 or higher occurred in 23.6% of the patients in the intismeran-pembrolizumab group and 20.3% of the patients in the placebo-pembrolizumab group. Eight patients (1.1%) in the intismeran-pembrolizumab group died from an adverse event; five of the deaths occurred before intismeran was administered. CONCLUSIONS: Adjuvant therapy with intismeran plus pembrolizumab significantly prolonged recurrence-free survival and distant-metastasis-free survival as compared with pembrolizumab alone in patients with completely resected, high-risk cutaneous melanoma. (Funded by Merck Sharp and Dohme and Moderna; ClinicalTrials.gov number, NCT05933577.).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.